Drilldown: Medicines
Use the filters below to narrow your results.
generic:
brand:
Fioricet, Esgic; with codeine as Fioricet with Codeine (Schedule III) (1) ·
Fiorinal; with codeine as Fiorinal with Codeine (Schedule III) (1) ·
Imodium, Imodium A-D (1) ·
Tylenol with Codeine #3 (30 mg codeine), Tylenol #4 (60 mg codeine), Capital with Codeine, Phenaphen with Codeine (1) ·
Ultracet, Tramacet (1)
classes:
None (1) ·
gut-restricted)]] (1) ·
weak)]] (1) ·
[[:Category:Antidiarrheals|Antidiarrheal]] (1) ·
[[:Category:Barbiturates|Barbiturate (butalbital)]] (2) ·
[[:Category:Fixed-dose_combinations|Fixed-dose combination]] (3) ·
[[:Category:Methylxanthines|Methylxanthine (caffeine)]] (2) ·
[[:Category:Non-opioid_analgesics|Non-opioid analgesic (acetaminophen)]] (2) ·
[[:Category:NSAIDs|NSAID (aspirin)]] (1) ·
[[:Category:Opioid_analgesics|Opioid analgesic (codeine (1) ·
[[:Category:Opioid_receptor_agonists|Peripheral opioid receptor agonist (μ-selective (1) ·
[[:Category:Schedule_III_controlled_substances|Schedule III controlled substance]] (2)
mechanism:
None (4) ·
'"`UNIQ--vote-00001513-QINU`"' The combination with acetaminophen provides additive non-opioid analgesia and lowers required codeine dose. CYP2D6 PGx is one of the most clinically actionable in current pharmacology; CPIC supports genotype-guided opioid selection'"`UNIQ--ref-00001514-QINU`"'. (1)
uses:
'"`UNIQ--vote-00000FCF-QINU`"', '"`UNIQ--vote-00000FD0-QINU`"', '"`UNIQ--vote-00000FD1-QINU`"' (1) ·
'"`UNIQ--vote-00001515-QINU`"', '"`UNIQ--vote-00001516-QINU`"' (1) ·
'"`UNIQ--vote-0000152F-QINU`"' (1) ·
'"`UNIQ--vote-0000159D-QINU`"', '"`UNIQ--vote-0000159E-QINU`"' (1) ·
'"`UNIQ--vote-000015B6-QINU`"' (1)
starting dose:
1-2 capsules (50 mg butalbital / 325 mg acetaminophen / 40 mg caffeine each) PO every 4 hours as needed; maximum 6 capsules/d (1) ·
1-2 capsules (50 mg butalbital / 325 mg aspirin / 40 mg caffeine each) PO every 4 hours as needed; maximum 6 capsules/d (1) ·
1-2 tablets (15-60 mg codeine, 300-600 mg acetaminophen) PO every 4-6 hours as needed (1) ·
2 tablets (75 mg tramadol / 650 mg acetaminophen) PO every 4-6 hours as needed; maximum 8 tablets/day for ≤5 days (1) ·
4 mg PO initially, then 2 mg after each loose stool, '''not to exceed 16 mg/d''' (8 mg OTC); chronic-use lower (1)
preparations:
2 mg capsules and tablets; 1 mg/5 mL oral solution; combined with simethicone (Imodium Multi-Symptom) (1) ·
50/325/40 mg capsules (1) ·
50/325/40 mg capsules and tablets; oral solution (1) ·
Codeine/acetaminophen 15/300 (#2 historical), 30/300 (#3), 60/300 (#4) mg tablets; 12/120 mg/5 mL elixir (1) ·
Tramadol/acetaminophen 37.5/325 mg tablets (1)
fda max:
16 mg/d (8 mg/d OTC) (1) ·
6 capsules/d (300 mg butalbital, 1950 mg acetaminophen, 240 mg caffeine) (1) ·
6 capsules/d (300 mg butalbital, 1950 mg aspirin, 240 mg caffeine) (1) ·
8 tablets/d (300 mg tramadol / 2600 mg acetaminophen); 5-day duration limit per label (1) ·
Acetaminophen 4 g/d absolute; codeine 240-360 mg/d typical practical limit (1)
routes:
onset: (Click arrow to add another value)
duration: (Click arrow to add another value)
halflife:
Butalbital ~35 hours (long; cumulative effects with frequent use); acetaminophen 1-3 hours; caffeine 3-7 hours'"`UNIQ--ref-0000159F-QINU`"' (1) ·
Butalbital ~35 hours; aspirin (acetyl group) ~15 minutes, salicylate 2-3 hours; caffeine 3-7 hours'"`UNIQ--ref-000015B7-QINU`"' (1) ·
Codeine 2.5-3.5 hours; acetaminophen 1-3 hours'"`UNIQ--ref-00001517-QINU`"' (1) ·
Tramadol ~5-7 hours (M1 metabolite ~9 hours); acetaminophen 1-3 hours'"`UNIQ--ref-00001530-QINU`"' (1) ·
~9-14 hours'"`UNIQ--ref-00000FD2-QINU`"' (1)
bioavailability:
Butalbital well-absorbed; aspirin 50-75%; caffeine ~100%'"`UNIQ--ref-000015B8-QINU`"' (1) ·
Butalbital well-absorbed; caffeine ~100%; acetaminophen 85-98%'"`UNIQ--ref-000015A0-QINU`"' (1) ·
Codeine ~60% (oral); acetaminophen 85-98%'"`UNIQ--ref-00001518-QINU`"' (1) ·
Tramadol ~75% (oral); acetaminophen 85-98%'"`UNIQ--ref-00001531-QINU`"' (1) ·
~0.3% (oral; extensive first-pass via CYP3A4 and P-glycoprotein-mediated efflux at the intestinal and blood-brain barriers limit systemic and CNS exposure at therapeutic doses)'"`UNIQ--ref-00000FD3-QINU`"' (1)
pregnancy:
None (1) ·
Avoid; neonatal opioid withdrawal documented.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Avoided; barbiturate + aspirin teratogenicity and bleeding concerns.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Generally avoided; barbiturate exposure in late pregnancy can produce neonatal withdrawal and respiratory depression.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Generally considered acceptable when needed.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
legal:
None (1) ·
OTC in US (1) ·
[[USLegal:Schedule III|Schedule III controlled substance]] in US (Fiorinal is scheduled federally; Fioricet with acetaminophen is unscheduled federally despite identical butalbital content, a regulatory quirk) (1) ·
[[USLegal:Schedule III|Schedule III controlled substance]] in US. '''Contraindicated in children <12''' for any indication and in any age post-tonsillectomy/adenoidectomy (FDA 2017 black-box advisory)'"`UNIQ--ref-00001519-QINU`"' (1) ·
[[USLegal:Schedule IV|Schedule IV controlled substance]] in US (tramadol was reclassified from non-controlled to Schedule IV in 2014 after recognition of dependence risk) (1)
Showing below up to 5 results in range #1 to #5.